Skip to main content
Contact Us
Subscribe
E-Edition
78°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Equillium Inc
(NQ:
EQ
)
1.560
+0.020 (+1.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Equillium Inc
< Previous
1
2
3
Next >
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
December 16, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
December 06, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
November 14, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
November 14, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
November 10, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
November 08, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
November 03, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
November 02, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
October 26, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
September 27, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
September 15, 2022
From
Equillium, Inc.
Via
Business Wire
EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to Shareholders
September 06, 2022
From
Halper Sadeh LLP
Via
Business Wire
Equillium to Acquire Metacrine in All-Stock Transaction
September 06, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
August 31, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
August 15, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
July 28, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
May 17, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
May 12, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
May 12, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
May 09, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
April 25, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
April 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
February 16, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Provides Timing Update on Conference Presentations
February 15, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
February 09, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
January 10, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 05, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.